Hanmi Pharm’s new oral anticancer drug ‘Oraxol starts global Phase III clinical trial
They will actively start the global Phase III clinical trial of Oraxol, an oral anticancer drug developed by Hanmi Pharm.
A Hanmi Pharm’s partner, Athenex(Nasdaq: ATNX) announced that the company completed the Phase III patient registration for ‘Oraxol,’ the Hanmi Pharm’s new anticancer drug whi...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.